MCID: END002
MIFTS: 53

Endometrioid Ovary Carcinoma

Categories: Cancer diseases, Endocrine diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Endometrioid Ovary Carcinoma

MalaCards integrated aliases for Endometrioid Ovary Carcinoma:

Name: Endometrioid Ovary Carcinoma 12 15
Endometrioid Carcinoma of Ovary 12 58
Ovarian Endometrioid Carcinoma 12 17
Endometrioid Carcinoma Ovary 12 70
Malignant Ovarian Endometrioid Tumor 70
Ovarian Endometrioid Tumor 70

Characteristics:

Orphanet epidemiological data:

58
endometrioid carcinoma of ovary
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Korea, Republic of),1-9/1000000 (Europe); Age of onset: Adult,Elderly; Age of death: adult,elderly;

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:5828
NCIt 50 C7979
SNOMED-CT 67 254852002
ICD10 via Orphanet 33 C56
UMLS via Orphanet 71 C0346163
Orphanet 58 ORPHA454723
UMLS 70 C0346163 C1335159 C1518231

Summaries for Endometrioid Ovary Carcinoma

Disease Ontology : 12 An ovary adenocarcinoma that has material basis in endometrial tissue.

MalaCards based summary : Endometrioid Ovary Carcinoma, also known as endometrioid carcinoma of ovary, is related to ovarian serous carcinoma and atypical polypoid adenomyoma. An important gene associated with Endometrioid Ovary Carcinoma is ARID1A (AT-Rich Interaction Domain 1A), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Downstream signaling events of B Cell Receptor (BCR). The drugs Bevacizumab and Atezolizumab have been mentioned in the context of this disorder. Affiliated tissues include ovary, lung and colon, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Endometrioid Ovary Carcinoma

Diseases related to Endometrioid Ovary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 231)
# Related Disease Score Top Affiliating Genes
1 ovarian serous carcinoma 30.3 WT1 TP53 KRAS
2 atypical polypoid adenomyoma 30.3 MLH1 CTNNB1
3 endometrial adenocarcinoma 29.7 TP53 PTEN MLH1 KRAS CTNNB1
4 lynch syndrome 28.8 TP53 PTEN POLE PIK3CA MSH6 MLH1
5 adenocarcinoma 28.6 TP53 PTEN POLE PIK3CA MSH6 MLH1
6 ovarian clear cell carcinoma 28.4 TP53 PTEN PPP2R1A PIK3CA MLH1 KRAS
7 endometrial cancer 28.2 WT1 TP53 PTEN PPP2R1A POLE PIK3CA
8 female reproductive endometrioid cancer 27.8 WT1 TP53 PTEN PPP2R1A POLE PIK3CA
9 ovarian cancer 27.8 WT1 TP53 PTEN POLE PIK3CA MSH6
10 endometriosis 10.4
11 thyroid hurthle cell adenoma 10.4 PTEN PIK3CA
12 vulvar intraepithelial neoplasia 10.3 TP53 CTNNB1
13 penile benign neoplasm 10.3 TP53 PIK3CA
14 parameningeal embryonal rhabdomyosarcoma 10.3 TP53 PIK3CA
15 pancreatic signet ring cell adenocarcinoma 10.3 TP53 KRAS
16 mammary analogue secretory carcinoma 10.3 TP53 CTNNB1
17 small-cell carcinoma of the ovary of hypercalcemic type 10.3 TP53 SMARCA4
18 adenosquamous lung carcinoma 10.3 PIK3CA KRAS
19 ovarian carcinosarcoma 10.3 TP53 PIK3CA ARID1A
20 serrated polyposis syndrome 10.3 PTEN KRAS
21 microcystic stromal tumor 10.3 WT1 CTNNB1
22 bone giant cell sarcoma 10.3 TP53 KRAS
23 fallopian tube carcinosarcoma 10.3 WT1 TP53
24 hemimegalencephaly 10.3 PTEN PIK3CA CTNNB1
25 vulvar disease 10.3 TP53 PTEN PIK3CA
26 ovarian seromucinous carcinoma 10.3 WT1 TP53
27 lung oat cell carcinoma 10.2 TP53 PTEN PIK3CA
28 ovarian mixed germ cell neoplasm 10.2 WT1 PIK3CA
29 vulva cancer 10.2 TP53 PTEN PIK3CA
30 liver angiosarcoma 10.2 TP53 KRAS
31 central nervous system benign neoplasm 10.2 TP53 PTEN CTNNB1
32 endocervical carcinoma 10.2 TP53 PIK3CA CTNNB1
33 oropharynx cancer 10.2 TP53 PIK3CA CTNNB1
34 cystadenocarcinoma 10.2 TP53 PPP2R1A PIK3CA
35 biliary tract benign neoplasm 10.2 TP53 KRAS
36 ovarian clear cell adenofibroma 10.2 PTEN PIK3CA KRAS
37 cystadenofibroma 10.2 WT1 TP53
38 peutz-jeghers syndrome 10.2 TP53 PTEN CTNNB1
39 breast carcinoma in situ 10.2 TP53 PIK3CA CTNNB1
40 gemistocytic astrocytoma 10.2 TP53 PTEN
41 malignant exocrine pancreas neoplasm 10.2 TP53 KRAS
42 small cell cancer of the lung 10.2 TP53 PTEN PIK3CA
43 embryonal sarcoma 10.2 TP53 CTNNB1
44 neuroblastoma 1 10.2 TP53 SMARCA4 PIK3CA
45 childhood medulloblastoma 10.2 TP53 SMARCA4 CTNNB1
46 tongue disease 10.2 TP53 PTEN CTNNB1
47 lipomatosis 10.2 PTEN PIK3CA KRAS
48 ductal carcinoma in situ 10.2 TP53 PTEN PIK3CA
49 basal cell nevus syndrome 10.2 TP53 PTEN CTNNB1
50 retinal cancer 10.2 TP53 PTEN CTNNB1

Graphical network of the top 20 diseases related to Endometrioid Ovary Carcinoma:



Diseases related to Endometrioid Ovary Carcinoma

Symptoms & Phenotypes for Endometrioid Ovary Carcinoma

GenomeRNAi Phenotypes related to Endometrioid Ovary Carcinoma according to GeneCards Suite gene sharing:

26 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.78 SMARCA4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-119 9.78 HNF1B
3 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.78 KRAS
4 Increased shRNA abundance (Z-score > 2) GR00366-A-155 9.78 MFSD14B
5 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.78 MFSD14B
6 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.78 ARID1B
7 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.78 SMARCA4
8 Increased shRNA abundance (Z-score > 2) GR00366-A-18 9.78 MFSD14B
9 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.78 MFSD14B
10 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.78 MFSD14B
11 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.78 KRAS
12 Increased shRNA abundance (Z-score > 2) GR00366-A-28 9.78 SMARCA4
13 Increased shRNA abundance (Z-score > 2) GR00366-A-34 9.78 MFSD14B
14 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.78 CTNNB1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.78 HNF1B
16 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.78 PIK3CA
17 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.78 KRAS
18 Increased shRNA abundance (Z-score > 2) GR00366-A-71 9.78 MFSD14B
19 Increased shRNA abundance (Z-score > 2) GR00366-A-72 9.78 ARID1B
20 Decreased sensitivity to paclitaxel GR00112-A-0 9.16 PTEN WT1
21 Increased NF-kappaB reporter expression GR00312-A 8.96 PIK3IP1 SERPINB11

MGI Mouse Phenotypes related to Endometrioid Ovary Carcinoma:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.32 ARID1A ARID1B CTNNB1 HNF1B KRAS MLH1
2 homeostasis/metabolism MP:0005376 10.31 ARID1A ARID1B CTNNB1 HNF1B KRAS MLH1
3 cellular MP:0005384 10.29 ARID1A CTNNB1 HNF1B KRAS MLH1 MSH6
4 hematopoietic system MP:0005397 10.25 ARID1A ARID1B CTNNB1 KRAS MLH1 MSH6
5 mortality/aging MP:0010768 10.25 ARID1A ARID1B CTNNB1 HNF1B KRAS MLH1
6 endocrine/exocrine gland MP:0005379 10.22 ARID1A CTNNB1 HNF1B KRAS MLH1 PIK3CA
7 embryo MP:0005380 10.19 ARID1A CTNNB1 HNF1B KRAS PIK3CA PTEN
8 integument MP:0010771 10.16 ARID1B CTNNB1 KRAS MLH1 MSH6 PIK3CA
9 neoplasm MP:0002006 10.1 ARID1A CTNNB1 KRAS MLH1 MSH6 PIK3CA
10 muscle MP:0005369 10.07 ARID1A ARID1B CTNNB1 HNF1B KRAS PIK3CA
11 liver/biliary system MP:0005370 9.98 CTNNB1 HNF1B KRAS PTEN SMARCA4 TP53
12 normal MP:0002873 9.86 ARID1A CTNNB1 KRAS PPP2R1A PTEN SMARCA4
13 renal/urinary system MP:0005367 9.56 ARID1B CTNNB1 HNF1B KRAS PTEN SMARCA4
14 pigmentation MP:0001186 9.55 CTNNB1 KRAS PTEN SMARCA4 TP53
15 respiratory system MP:0005388 9.17 CTNNB1 KRAS MLH1 PTEN SMARCA4 TP53

Drugs & Therapeutics for Endometrioid Ovary Carcinoma

Drugs for Endometrioid Ovary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 20)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 2 216974-75-3
2
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
3
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
4
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
5
Cysteine Approved, Nutraceutical Phase 2 52-90-4 5862
6 Angiogenesis Inhibitors Phase 2
7 Antineoplastic Agents, Immunological Phase 2
8 Immunoglobulins Phase 2
9 Immunoglobulins, Intravenous Phase 2
10 Antibodies Phase 2
11 Antibodies, Monoclonal Phase 2
12 Respiratory System Agents Phase 2
13 topoisomerase I inhibitors Phase 2
14 Antidotes Phase 2
15 Antioxidants Phase 2
16 Protective Agents Phase 2
17 Anti-Infective Agents Phase 2
18 Expectorants Phase 2
19 Antiviral Agents Phase 2
20 N-monoacetylcystine Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Halting Early Advancement of Residual Disease by Treatment With Bevacizumab and Atezolizumab in Ovarian Cancer Not yet recruiting NCT04510584 Phase 2 Atezolizumab;Bevacizumab
2 Evaluation of the Addition of N-Acetylcysteine to Topotecan in the Tumor Microenvironment of Persistent or Recurrent High Grade Endometrioid or Serous Ovarian Carcinoma Terminated NCT02569957 Phase 2 Topotecan Hydrochloride;Topotecan Hydrochloride;Acetylcysteine
3 Correlation of PTEN and IGFBP-3 in the Invasion of Ovarian Endometrioid Carcinoma Withdrawn NCT00173407

Search NIH Clinical Center for Endometrioid Ovary Carcinoma

Genetic Tests for Endometrioid Ovary Carcinoma

Anatomical Context for Endometrioid Ovary Carcinoma

MalaCards organs/tissues related to Endometrioid Ovary Carcinoma:

40
Ovary, Lung, Colon, Thyroid, Breast, Skin, Cervix

Publications for Endometrioid Ovary Carcinoma

Articles related to Endometrioid Ovary Carcinoma:

(show top 50) (show all 120)
# Title Authors PMID Year
1
Implications for management of ovarian cancer in a transgender man: Impact of androgens and androgen receptor status. 61
33663874 2021
2
WT1 Positive Ovarian Endometrioid Tumors: Observations From Consult Cases and Strategies for Distinguishing From Serous Neoplasms. 61
33782345 2021
3
CTNNB1 Mutations and Aberrant β-Catenin Expression in Ovarian Endometrioid Carcinoma: Correlation With Patient Outcome. 61
32769429 2021
4
Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma. 61
33758607 2021
5
CTNNB1 p.L31P mutation in an ovarian endometrioid carcinoma with synchronous uterine endometrioid carcinoma. 61
33120166 2020
6
A Wolf in Sheep's Clothing: High-Grade Ovarian Endometrioid Carcinoma Masquerading as Pregnancy. 61
32821580 2020
7
Ovarian endometrioid carcinoma resembling sex cord-stromal tumor: A case report. 61
32607341 2020
8
Endometriosis-associated ovarian cancer is not a distinct clinical entity among young patients: A 12-year cohort study. 61
31837932 2020
9
Assessing CT imaging features combined with CEA and CA125 levels to identify endometriosis-associated ovarian cancer. 61
32424610 2020
10
Malignant risk of pelvic mass after hysterectomy for adenomyosis or endometriosis. 61
32282727 2020
11
p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis. 61
31335355 2019
12
A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. 61
31239549 2019
13
Ovarian Endometrioid Carcinoma Misdiagnosed as Mucinous Carcinoma: An Underrecognized Problem. 61
30480647 2019
14
Metachronous ovarian endometrioid carcinomas in a patient with a PTEN variant: case report of incidentally detected Cowden syndrome. 61
31664961 2019
15
Fertility-Sparing surgery for young women with ovarian endometrioid carcinoma: a multicenteric comparative study using inverse probability of treatment weighting. 61
31517302 2019
16
A COEUR cohort study of SATB2 expression and its prognostic value in ovarian endometrioid carcinoma. 61
30924313 2019
17
Alterations in β-catenin, microsatellite instability, and HNF-1β levels are independently associated with ovarian endometriosis-associated tumorigenesis. 61
31022415 2019
18
HPV DNA integration site as proof of the origin of ovarian metastasis from endocervical adenocarcinoma: three case reports. 61
31014281 2019
19
FIGO Versus Silverberg Grading Systems in Ovarian Endometrioid Carcinoma: A Comparative Prognostic Analysis. 61
30212391 2019
20
Nuclear β-catenin and CDX2 expression in ovarian endometrioid carcinoma identify patients with favourable outcome. 61
30326146 2019
21
Prognostic factors of synchronous endometrial and ovarian endometrioid carcinoma. 61
30479091 2019
22
Microcystic, Elongated, and Fragmented Pattern Invasion in Ovarian Endometrioid Carcinoma. 61
29369921 2018
23
Malignant Female Adnexal Tumor of Probable Wolffian Origin: Case Report and Literature Review. 61
28700436 2018
24
Cytomorphologic features of metastatic endometrioid carcinoma by fine needle aspiration. 61
29105363 2018
25
Origin of clear cell carcinoma: nature or nurture? 61
29178260 2018
26
Microcystic, Elongated, and Fragmented Pattern Invasion in Ovarian Endometrioid Carcinoma: Immunohistochemical Profile and Prognostic Implications. 61
28319570 2018
27
Prognostic and Clinicopathological Significance of ARID1A in Endometrium-Related Gynecological Cancers: A Meta-Analysis. 61
28466574 2017
28
Risk of second primary cancers in women diagnosed with endometrial cancer in German and Swedish cancer registries. 61
28815572 2017
29
Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups. 61
28776572 2017
30
Prognostic analysis for Chinese patients with stage I ovarian endometrioid carcinoma. 61
28923080 2017
31
Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma. 61
28417598 2017
32
Expression of protease-activated receptor-2 (PAR-2) is related to advanced clinical stage and adverse prognosis in ovarian clear cell carcinoma. 61
28438620 2017
33
Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications. 61
28264438 2017
34
Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report. 61
28103826 2017
35
Metastatic endometrial endometrioid carcinoma mimicking pilomatrixoma of the distal vagina. 61
28130284 2017
36
Impact of oviductal versus ovarian epithelial cell of origin on ovarian endometrioid carcinoma phenotype in the mouse. 61
27538791 2016
37
Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas. 61
26799366 2016
38
Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality. 61
26832771 2016
39
Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors. 61
26551621 2016
40
Ovarian endometrioid carcinoma with yolk sac tumor component in a postmenopausal woman. 61
29943939 2016
41
Distinct β-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas. 61
26276776 2015
42
Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma. 61
26166557 2015
43
MiR-191 modulates malignant transformation of endometriosis through regulating TIMP3. 61
25819812 2015
44
Early-stage endometrioid ovarian carcinoma: population-based outcomes in British Columbia. 61
25188885 2014
45
Novel insights on the malignant transformation of endometriosis into ovarian carcinoma. 61
24905724 2014
46
A rare case of synchronous right ovarian clear cell carcinoma and an incidental left ovarian endometrioid carcinoma with immunohistochemical study. 61
24970988 2014
47
Frequent POLE1 p.S297F mutation in Chinese patients with ovarian endometrioid carcinoma. 61
24472300 2014
48
Unilateral Optic Disc Papilloedema following Administration of Carboplatin Chemotherapy for Ovarian Carcinoma. 61
24575012 2014
49
Low-grade endometrioid carcinoma of the ovary associated with undifferentiated carcinoma: case report and review of the literature. 61
25120828 2014
50
Epithelial-to-mesenchymal transition and stem cells in endometrial cancer. 61
23845467 2013

Variations for Endometrioid Ovary Carcinoma

Cosmic variations for Endometrioid Ovary Carcinoma:

9 (show top 50) (show all 2466)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM93210112 TP53 ovary,NS,carcinoma,undifferentiated carcinoma c.584T>A p.I195N 17:7674947-7674947 12
2 COSM106086441 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.772G>T p.E258* 17:7674191-7674191 12
3 COSM87906616 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.725G>T p.C242F 17:7674238-7674238 12
4 COSM144701147 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.706T>G p.C236G 17:7673797-7673797 12
5 COSM112265718 TP53 ovary,NS,carcinoma,undifferentiated carcinoma c.376-2A>G p.? 17:7675238-7675238 12
6 COSM144651195 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.605C>T p.S202F 17:7674241-7674241 12
7 COSM142565804 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.724G>C p.D242H 17:7673779-7673779 12
8 COSM142560924 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.371A>G p.Y124C 17:7675124-7675124 12
9 COSM144019837 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.451A>G p.I151V 17:7675128-7675128 12
10 COSM143951263 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.234G>T p.M78I 17:7674252-7674252 12
11 COSM122271391 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.263A>G p.Y88C 17:7674872-7674872 12
12 COSM122278514 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.329G>T p.C110F 17:7674238-7674238 12
13 COSM144328531 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.555+1G>A p.? 17:7674858-7674858 12
14 COSM93183307 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.524G>A p.R175H 17:7675088-7675088 12
15 COSM144291732 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.483G>C p.K161N 17:7673568-7673568 12
16 COSM144086975 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.47G>A p.R16H 17:7675088-7675088 12
17 COSM106053828 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.488A>G p.Y163C 17:7675124-7675124 12
18 COSM145017944 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.625C>T p.R209W 17:7674221-7674221 12
19 COSM145017479 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.542A>G p.Y181C 17:7674872-7674872 12
20 COSM105630090 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.770T>G p.L257R 17:7674193-7674193 12
21 COSM144013113 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.491G>A p.R164H 17:7675088-7675088 12
22 COSM144311667 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.310G>A p.V104M 17:7675185-7675185 12
23 COSM121883757 TP53 ovary,NS,carcinoma,undifferentiated carcinoma c.379G>T p.D127Y 17:7674188-7674188 12
24 COSM122989744 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.564G>C p.K188N 17:7673568-7673568 12
25 COSM144087035 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.182A>G p.Y61C 17:7674872-7674872 12
26 COSM122273499 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.218A>G p.Y73C 17:7674917-7674917 12
27 COSM144311880 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.497A>G p.Y166C 17:7674917-7674917 12
28 COSM93185001 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.843C>G p.D281E 17:7673777-7673777 12
29 COSM142562224 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.263C>T p.S88F 17:7675232-7675232 12
30 COSM105627860 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.725G>T p.C242F 17:7674238-7674238 12
31 COSM144069809 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.807A>T p.R269S 17:7673780-7673780 12
32 COSM112253220 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.659A>G p.Y220C 17:7674872-7674872 12
33 COSM143157326 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.11A>G p.Y4C 17:7675124-7675124 12
34 COSM93183388 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.725G>A p.C242Y 17:7674238-7674238 12
35 COSM144087273 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.265C>T p.R89W 17:7674221-7674221 12
36 COSM87898578 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.733G>A p.G245S 17:7674230-7674230 12
37 COSM112260228 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.725G>T p.C242F 17:7674238-7674238 12
38 COSM122271726 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.284C>T p.S95F 17:7674283-7674283 12
39 COSM143158810 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.-98C>T p.? 17:7675232-7675232 12
40 COSM121884713 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.184C>T p.L62F 17:7674951-7674951 12
41 COSM143370705 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.542A>G p.Y181C 17:7674872-7674872 12
42 COSM111778964 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.423C>G p.C141W 17:7675189-7675189 12
43 COSM111758868 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.742C>T p.R248W 17:7674221-7674221 12
44 COSM106052917 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.524G>A p.R175H 17:7675088-7675088 12
45 COSM143955612 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.323G>C p.R108P 17:7673820-7673820 12
46 COSM112253807 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.733G>A p.G245S 17:7674230-7674230 12
47 COSM122272158 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.92A>G p.Y31C 17:7675124-7675124 12
48 COSM143764938 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.828T>G p.S276= 17:7673583-7673583 12
49 COSM142838247 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.991C>T p.Q331* 17:7673537-7673537 12
50 COSM144684943 TP53 ovary,NS,carcinoma,endometrioid carcinoma c.655G>T p.E219* 17:7674191-7674191 12

Expression for Endometrioid Ovary Carcinoma

Search GEO for disease gene expression data for Endometrioid Ovary Carcinoma.

Pathways for Endometrioid Ovary Carcinoma

Pathways related to Endometrioid Ovary Carcinoma according to GeneCards Suite gene sharing:

(show all 37)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.88 TP53 PTEN PPP2R1A PIK3CA KRAS CTNNB1
2
Show member pathways
12.64 TP53 PTEN PPP2R1A PIK3CA KRAS
3 12.64 TP53 PTEN PIK3CA MSH6 MLH1 KRAS
4
Show member pathways
12.61 TP53 PTEN PIK3CA KRAS CTNNB1
5
Show member pathways
12.58 TP53 PTEN PIK3CA MSH6 KRAS
6
Show member pathways
12.56 TP53 PTEN PIK3CA MSH6 MLH1 KRAS
7 12.46 TP53 PTEN PIK3CA KRAS
8
Show member pathways
12.44 TP53 PTEN PIK3CA KRAS
9
Show member pathways
12.43 TP53 PTEN PIK3CA KRAS
10 12.38 TP53 SMARCA4 PPP2R1A MSH6 MLH1
11
Show member pathways
12.36 TP53 PIK3CA KRAS CTNNB1
12 12.35 TP53 SMARCA4 HNF1B CTNNB1
13
Show member pathways
12.28 TP53 PTEN KRAS CTNNB1
14 12.26 TP53 PTEN PIK3CA KRAS
15
Show member pathways
12.24 TP53 PTEN PIK3CA CTNNB1
16 12.22 TP53 PIK3CA KRAS CTNNB1
17
Show member pathways
12.16 TP53 PTEN PIK3CA KRAS
18 12.05 TP53 PTEN PIK3CA KRAS
19 12.02 TP53 MSH6 MLH1 KRAS CTNNB1
20 11.97 TP53 SMARCA4 PTEN MLH1
21
Show member pathways
11.94 TP53 SMARCA4 PTEN PIK3CA MLH1 KRAS
22 11.92 TP53 PIK3CA KRAS CTNNB1
23 11.84 TP53 PTEN KRAS CTNNB1
24
Show member pathways
11.81 POLE MSH6 MLH1
25 11.79 TP53 PTEN PIK3CA
26 11.77 TP53 POLE MSH6
27
Show member pathways
11.74 TP53 SMARCA4 MSH6
28 11.73 TP53 PTEN PPP2R1A PIK3CA KRAS
29
Show member pathways
11.65 SMARCA4 ARID1B ARID1A
30 11.64 TP53 PIK3CA MSH6 MLH1
31 11.62 TP53 SMARCA4 PTEN MSH6 KRAS CTNNB1
32 11.61 TP53 PTEN PIK3CA KRAS CTNNB1
33 11.6 TP53 PTEN PIK3CA KRAS
34 11.55 TP53 PTEN PIK3CA ARID1A
35 11.51 TP53 PTEN PIK3CA
36 11.41 TP53 PTEN MSH6
37 11.18 PTEN PIK3CA KRAS

GO Terms for Endometrioid Ovary Carcinoma

Cellular components related to Endometrioid Ovary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 10 WT1 TP53 SMARCA4 PTEN POLE MSH6
2 npBAF complex GO:0071564 9.37 SMARCA4 ARID1A
3 mismatch repair complex GO:0032300 9.32 MSH6 MLH1
4 brahma complex GO:0035060 9.16 ARID1B ARID1A
5 SWI/SNF complex GO:0016514 9.13 SMARCA4 ARID1B ARID1A
6 nBAF complex GO:0071565 8.8 SMARCA4 ARID1B ARID1A

Biological processes related to Endometrioid Ovary Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 10.11 WT1 TP53 SMARCA4 HNF1B CTNNB1 ARID1B
2 nervous system development GO:0007399 9.85 SMARCA4 PTEN CTNNB1 ARID1B ARID1A
3 response to drug GO:0042493 9.81 TP53 PTEN HNF1B CTNNB1
4 positive regulation of gene expression GO:0010628 9.8 WT1 TP53 PTEN KRAS CTNNB1
5 positive regulation of DNA-binding transcription factor activity GO:0051091 9.76 SMARCA4 PTEN CTNNB1
6 heart development GO:0007507 9.73 WT1 TP53 PTEN CTNNB1
7 chromatin remodeling GO:0006338 9.71 SMARCA4 ARID1B ARID1A
8 liver development GO:0001889 9.65 PIK3CA KRAS HNF1B
9 negative regulation of phosphatidylinositol 3-kinase signaling GO:0014067 9.58 PTEN PIK3IP1
10 isotype switching GO:0045190 9.56 MSH6 MLH1
11 somatic hypermutation of immunoglobulin genes GO:0016446 9.55 MSH6 MLH1
12 regulation of synaptic transmission, GABAergic GO:0032228 9.52 PTEN KRAS
13 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.5 WT1 TP53 SMARCA4
14 chromatin-mediated maintenance of transcription GO:0048096 9.49 ARID1B ARID1A
15 embryonic organ development GO:0048568 9.43 TP53 POLE CTNNB1
16 somatic recombination of immunoglobulin gene segments GO:0016447 9.37 MSH6 MLH1
17 ATP-dependent chromatin remodeling GO:0043044 9.33 SMARCA4 ARID1B ARID1A
18 negative regulation of cell growth GO:0030308 9.26 WT1 TP53 SMARCA4 PPP2R1A
19 positive regulation of transcription, DNA-templated GO:0045893 9.17 WT1 TP53 SMARCA4 HNF1B CTNNB1 ARID1B

Molecular functions related to Endometrioid Ovary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.97 WT1 TP53 SMARCA4 POLE MSH6 HNF1B
2 transcription coactivator activity GO:0003713 9.56 SMARCA4 CTNNB1 ARID1B ARID1A
3 chromatin binding GO:0003682 9.55 TP53 POLE MSH6 MLH1 CTNNB1
4 enzyme binding GO:0019899 9.35 TP53 PTEN MSH6 MLH1 CTNNB1
5 mismatched DNA binding GO:0030983 9.32 MSH6 MLH1
6 guanine/thymine mispair binding GO:0032137 8.62 MSH6 MLH1

Sources for Endometrioid Ovary Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....